Cellular immunotherapy in multiple myeloma: Lessons from preclinical models

被引：20

作者：

Binsfeld, M. ^{[1
]}

Fostier, K. ^{[2
]}

Muller, J. ^{[1
]}

Baron, F. ^{[1
,3
,4
]}

Schots, R. ^{[2
]}

Beguin, Y. ^{[1
,3
,4
]}

Heusschen, R. ^{[1
]}

Caers, J. ^{[1
,3
,4
]}

机构：

[1] Univ Liege, GIGA Res, Hematol Lab, B-4000 Liege, Belgium

[2] Univ Ziekenhuis Brussel UZ Brussel, Dept Clin Hematol, Brussels, Belgium

[3] Univ Liege, Div Hematol, Dept Med, B-4000 Liege, Belgium

[4] CHU Liege, Liege, Belgium

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2014年 / 1846卷 / 02期

关键词：

Multiple myeloma; Mouse models; Immunotherapy; Transplantation; Adoptive transfer; Vaccination; REGULATORY T-CELLS; NATURAL-KILLER-CELLS; COMPLEX CLASS-II; PROTECTIVE IMMUNE-RESPONSES; MARROW STROMAL CELLS; DENDRITIC CELLS; BONE-MARROW; SUPPRESSOR-CELLS; ANTITUMOR IMMUNITY; PERIPHERAL-BLOOD;

D O I：

10.1016/j.bbcan.2014.08.001

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The majority of multiple myeloma patients relapse with the current treatment strategies, raising the need for alternative therapeutic approaches. Cellular immunotherapy is a rapidly evolving field and currently being translated into clinical trials with encouraging results in several cancer types, including multiple myeloma. Murine multiple myeloma models are of critical importance for the development and refinement of cellular immunotherapy. In this review, we summarize the immune cell changes that occur in multiple myeloma patients and we discuss the cell-based immunotherapies that have been tested in multiple myeloma, with a focus on murine models. (C) 2014 Elsevier B.V. All rights reserved.

引用

页码：392 / 404

页数：13

共 50 条

[31] Immunotherapy in multiple myeloma
Canto, Pedro Asensi
Herraiz, Mario Arnao
Comos, Javier de la Rubia
[J]. MEDICINA CLINICA, 2024, 162 (10): : 485 - 493
[32] A Novel Strategy for Repairing Multiple Myeloma Bone Lesions: Lessons From Murine Models
Calvi, Laura M.
Hofbauer, Lorenz C.
[J]. JOURNAL OF BONE AND MINERAL RESEARCH, 2019, 34 (05) : 781 - 782
[33] The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception
Dhodapkar, Madhav, V
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S4 - S12
[34] Surveying surface antigen expression in multiple myeloma preclinical models.
Morisot, Nadege
Tam, Julian
Dailey, Nicole
Davis, Tina
Chen, Jacinda
Islar, Janeen
Buren, Luxuan
Patel, Nitin
Lazetic, Sasha
Chan, Ivan
Trager, James B.
Tan, Joanne B.
[J]. CANCER RESEARCH, 2022, 82 (12)
[35] Evaluation of Mcl-1 Inhibitors in Preclinical Models of Multiple Myeloma
Belmonte, Matthew A.
Adam, Ammar
Borrelli, Deanna
Bhavsar, Deepa
Bebernitz, Christina
Hird, Alexander
Secrist, Paul
[J]. BLOOD, 2014, 124 (21)
[36] Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model
Thirukkumaran, Chandini M.
Shi, Zhong Qiao
Nuovo, Gerard J.
Luider, Joanne
Kopciuk, Karen A.
Dong, Yuan
Mostafa, Ahmed A.
Thakur, Satbir
Gratton, Kathy
Yang, Ailian
Chin, Alex C.
Coffey, Matt C.
Jimenez-Zepeda, Victor H.
Stewart, Douglas
Chesi, Marta
Bergsagel, P. Leif
Morris, Don
[J]. BLOOD ADVANCES, 2019, 3 (05) : 797 - 812
[37] Immunotherapy for high grade glioma: Lessons from preclinical and clinical experiences
Stefaan, Van Gool
Hilko, Ardon
Wim, Maes
Tina, Verschuere
Lien, Vandenberk
Steven, De Vleeschouwer
[J]. JOURNAL OF NEUROIMMUNOLOGY, 2010, 228 (1-2) : 70 - 71
[38] T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current Developments
Simmons, Gary L.
Puglianini, Omar Castaneda
[J]. CANCERS, 2022, 14 (17)
[39] Cellular immunotherapy for plasma cell myeloma
A L Garfall
D T Vogl
B M Weiss
E A Stadtmauer
[J]. Bone Marrow Transplantation, 2013, 48 : 1377 - 1386
[40] Cellular immunotherapy for plasma cell myeloma
Garfall, A. L.
Vogl, D. T.
Weiss, B. M.
Stadtmauer, E. A.
[J]. BONE MARROW TRANSPLANTATION, 2013, 48 (11) : 1377 - 1386

← 1 2 3 4 5 →